Medulloblastoma - 50 Studies Found Recruiting : Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma : High-risk Medulloblastoma : 2013-12-30 : Drug: Carboplatin + etoposide Completed : Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma : Recurrent Childhood Medulloblastoma : 2010-11-10 : Other: Laboratory Biomarker Analysis Not yet recruiting : Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma : Untreated Childhood Medulloblastoma : 2016-03-25 : Drug: Cisplatin Given IV Completed : Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma : Untreated Childhood Medulloblastoma : 2013-12-13 : Drug: Vincristine Sulfate Give Completed : GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment : Recurrent Childhood Medulloblastoma : 2009-01-13 : Drug: vismodegib Given orally Completed : Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma : Untreated Childhood Medulloblastoma : 2004-06-14 : Drug: Cisplatin Given IV Withdrawn : A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma : Medulloblastoma, Childhood Rhabdomyosarcoma : 2012-09-28 : Drug: LY2940680 Capsule admini Recruiting : Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway : Histologically Confirmed Medulloblastoma Activation of the Soni : 2012-05-15 : Drug: vismodegib Hedgehog path Recruiting : Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor : Medulloblastoma Neuroectodermal Tumor : 2010-07-22 : Biological: TTRNA-xALT TTRNA-x Terminated : Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma : Neuroblastoma Medulloblastoma : 2011-11-28 : Drug: TPI 287 Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Day <<< Previous | Next >>>